Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has ...
Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and ...
RFG Advisory LLC boosted its position in Eli Lilly and Company (NYSE:LLY – Free Report) by 13.4% in the fourth quarter, ...
Private Capital Advisors Inc. grew its holdings in shares of Eli Lilly and Company (NYSE:LLY – Free Report) by 0.1% during ...
Eli Lilly’s crop of new products propelled ... s chief financial officer Josh Smiley on the company’s results call, adding that Trulicity “grew faster than the market, hosting an increase ...
Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.
The company’s main products include Humalog, Trulicity, Alimta, and Taltz. Eli Lilly and Company (NYSE:LLY) also focuses on RNA and DNA-based therapies at its Lilly Seaport Innovation Center.
Eli Lilly and Company discovers, develops ... Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It provides oncology products, including Alimta, Cyramza, Erbitux ...
Roughly $15 billion of this total stems from just three drugs -- Mounjaro, Zepbound, and Trulicity ... when it comes to an investment in Eli Lilly. The company is well diversified and is ...